Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Deferred Tax Liability of $44.7 million for Q4 2025, up 628.73% year-over-year from $6.1 million in Q4 2024, and up 628.73% quarter-over-quarter from $6.1 million in Q4 2024.
Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $44.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 628.73% year-over-year to $44.7 million; the TTM figure through Dec 2025 stood at $44.7 million (up 628.73% YoY), while the FY2025 annual figure was $44.7 million, up 671.33% from the prior year.
- Non-Current Deferred Tax Liability improved to $44.7 million in Q4 2025 per TLX's latest filing, from $6.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $44.7 million in Q4 2025 and bottomed at $6.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2024 | 6.13 Mn |
| Dec 31, 2024 | 6.13 Mn |